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THE ROLE OF TELOMERES IN PULMONARY FIBROSIS  
AND  
ITS EFFECTS ON CHOICE OF TREATMENT 
 
LANA KASS-GERGI 
ABSTRACT 
  
 Idiopathic pulmonary fibrosis (IPF) is an aggressive disease with no known 
origin. Scar tissue continues to build up in the lungs diminishing pulmonary function. 
Without successful treatment, patients with IPF have a mean survival of 5 years after 
diagnosis. Though the exact etiology of IPF is unknown, studies have established a role 
of telomeres in 25% or more of familial or sporadic cases. Mutations in the genes that 
encode for the components of telomerase have been implicated as the cause of the 
telomere dysfunction seen in these cases. The mutations examined below include TERT, 
TERC, RTEL1, TINF2, and PARN.  
With this link in mind, the available and the researched treatment plans are 
discussed. Of the discussed therapies, the researched treatment options that target the 
telomere-specific cases of IPF are a synthetic sex hormone (danazol), stem cell therapy, 
and a small molecule activator (GRN510). The remaining treatment plans discussed 
target either the direct cause of symptoms or the symptoms themselves. These studied 
options include N-acetylcysteine, prednisone, azathioprine, pirfenidone, nintedanib (with 
 v
and without statins), and low-dose inhaled carbon monoxide. The treatment options with 
the favored positive results are danazol and nintedanib.  
 vi
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INTRODUCTION 
 Telomeres: Structure and Function in Cell Regulation 
 Human cells contain their DNA in structures called chromosomes in the 
nucleus of the cell. These chromosomes consist of very tightly coiled DNA strands 
wrapped around histones, the proteins that provide structure support. When the cell 
is dividing, the chromosomes unwind in order for the DNA to be replicated for the 
new forming cell. A combination of four chemical bases (adenine (A), cytosine 
(C), guanine (G), and thymine (T)) is paired off to create the double stranded 
structure of DNA. The sequence of these bases (the variant parts of nucleotides) 
determines what information is encoded in the DNA. Since DNA contains the 
genetic material that serves as a template for which all of an organism is built and 
maintained, it is necessary to have the exact same DNA sequence in almost every 
cell of the human body. During the process of normal DNA replication, DNA 
strands are shortened from the ends inward due to the organization of the genetic 
material and the replication machinery (i.e. DNA and RNA polymerases) of the 
cell (Figure 1). Thus, the presence of non-coding genetic material (or material that 
does not contain any information necessary for the creation or maintenance of the 
organism) at the ends of DNA strands is needed to protect the remainder of genetic 
material from degradation. The non-coding material at the ends of DNA are called 
telomeres. 
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Figure 1—The DNA Replication Problem: DNA is replicated by separating the 
two parent strands and then adding complementary daughter ones to each strand. 
Because the parent strands are separated, one parent strand is oriented in a 5’ to 3’ 
direction (leading strand) and the other is oriented in a 3’ to 5’ direction (lagging 
strand) at the time of replication. As a result of DNA polymerase’s limitations to 
only add nucleotides to a 3’ end of DNA sequence and in a 5’ to 3’ direction, the 
lagging strand is replicated in pieces (known as Okazaki fragments). RNA primers 
are continuously added to the lagging strand as the parental strands are further 
separated and DNA polymerase adds DNA nucleotides to 3’ end of the primers. 
These primers are later removed and replaced with DNA nucleotides where there 
are 3’ ends of DNA. When the RNA primers are removed, there would exist a 
section of parental-strand DNA left unmatched at the 5’ end of the daughter strand 
and, subsequently, removed in every consequent replication. (Adapted from 
“Boundless Biology”, 2013 (5))  
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Telomeres are repeated sequences of the nucleic acid base pairs TTAGGG. 
Telomerases are enzymes that regenerate and restore telomeres (Figure 3). While 
they are expressed and active in certain cell lines (germ cells, hematopoietic cells), 
when they are inappropriately activated in somatic cell lines, immortalization and 
malignancy can result. Telomerase consists of an RNA subunit, known as TERC 
(TR), and a catalytic protein that has reverse transcriptase ability, TERT (Figure 
2). These subunits are required to be functional in order for telomeres to be 
maintained with every cell division. In addition to the subunits that make up the 
enzyme, a shelterin complex associated to telomeres is made up of six proteins: 
TRF1, TRF2, POT1, TIN2, TPP1, and Rap1 (Figure 2). These subunits come 
together to surround the repeated telomere sequence, TTAGGG, to shield it from 
being recognized by the DNA repair machinery, which would process the telomere 
as damaged DNA. 1 
With every mitotic event (cell division), there is a natural, physiological 
shortening of telomeres. In addition to this, telomeres are also shortened in human 
cells through the “wear and tear” events of aging (which includes damage done by 
oxygen radicals and environmental toxins and exposures). Once the telomeres have 
reached a length threshold, healthy cells will respond by undergoing apoptosis or 
entering senescence. If the function of telomerases is not regulated, telomeres can 
repeatedly be elongated and a cell can continue to divide beyond the normal (or 
healthy) amount. When this occurs, these cells are labeled  “cancerous.” 
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Figure 2 – Telomerase Structure: A) The shelterin complex is composed 
of the 6 proteins shown. The function of the complex is to protect the 
telomere from being read as a mistake during DNA replication.2 B) The 
subunits TERT and TERC make up the telomerase enzyme, which 
functions to create and regenerate the telomere. (Adapted from A) 
Ishikawa, Fuyuki, 2013 (4) & B) Kinwan, M. and Dokan, I., 2009 (3)) 
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of the 6 proteins shown. The function of the complex is to protect the 
telomere from being read as a mistake during DNA replication.2 B) The 
subunits TERT and TERC make up the telomerase enzyme, which 
functions to create and regenerate the telomere. (Adapted from A) 
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Figure 3—Telomerase Activity: Telomerase uses an RNA 
component to attach to the DNA overhang and synthesizes a 
complement to its own repetitive sequence in a 5’ to 3’ direction 
before relocating and repeating. As the enzyme synthesizes further 
down, DNA polymerase adds to the sequence in a 5’ to 3’ 
direction. (Adapted from Lecture Presentations from Campbell 
Biology, 9th Edition, 2011 (2)) 
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While unregulated elongation of telomeres is linked to various cancers, 
accelerated shortening of telomeres has been found to increase the risk of many 
pathophysiological states. This accelerated shortening can be a result of 
environmental exposures from diet and lifestyle choices, such as smoking or 
alcohol misuse.1 The environmental causes of this shortening lead to an increased 
need for cell replacement, as they are damaging the affected tissue. This need for 
new cells means undergoing more cell divisions, which leads to increased rate of 
telomere attrition (shortening). 1 In addition to environmental exposures, there 
exist genetic predispositions to rapid shortening of telomeres and this process has 
been associated with several inherited disorders of rapid, premature aging.1 
Mutations in the genes that code for the components of the telomerase enzyme, 
TERT and TERC, as well as the genes that code for those genes’ regulation, can be 
inherited. These mutations result in a dysfunctional enzyme.1 Older adults with 
shorter telomeres have been found to be at increased risk of coronary artery 
disease, myocardial infarctions, and osteoporosis than peers with longer 
telomeres.1 
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Idiopathic Pulmonary Fibrosis  
 Pulmonary fibrosis, a disease in which dense and rigid scar tissue 
builds up in lung tissue making the lungs deficient in their function (Figure 4), is 
said to be idiopathic when the cause of the pathology is unknown.6 “Idiopathic 
pulmonary fibrosis (IPF), the most common form of the idiopathic interstitial 
pneumonias, is a chronic, progressive, irreversible, and usually lethal lung disease 
of unknown cause.”7 IPF is thought to be the result of excessive and unprovoked 
production of inflammatory mediators by alveolar macrophages. These 
inflammatory mediators activate fibroblasts to produce dense collagen deposits and 
stimulate the hyperplasia of type II pneumocytes causing the characteristic 
histopathologic findings necessary for diagnosis of this disease. 7 
The pathogenesis of the disease varies in timeline among patients. While 
IPF may progress slowly in some, it also may cause a quick decline in a patient’s 
condition. Affecting between 4.6 and 16.3 in 100,000 people every year, with 
incidence rising, IPF has been found in mostly middle-aged and elderly adults. 
Cases of IPF are more common in men than in women with a ratio of incidence of 
1.5-1.7 to 1.4 Progression of the disease may lead to other issues such as a 
collapsed lung, lung infections, blood clots in the lung, and lung cancer.6 In IPF 
patients, the most common cause of death is respiratory failure, with other causes 
including pulmonary hypertension, heart failure, pulmonary embolism, pneumonia, 
and lung cancer.6 Factors that may increase the risk of developing IPF include 
cigarette smoking, viral infections (Epstein-Barr virus, influenza A virus, hepatitis 
 8 
C virus, HIV, and herpes virus 6, family history of IPF, and gastroesophageal 
reflux disease (GERD).6 
The primary symptom of IPF is shortness of breath. Initially, this dyspnea 
will occur only during exercise, but it will likely become a symptom at rest, as 
well. The other most common symptom is a dry, hacking cough with no signs of 
improvement.6 As a result of a “relatively slow clinical course,” patients often seek 
medical treatment after months to years of initial symptoms, when they have 
chronic and progressively worsening exertional dyspnea (difficulty breathing) and 
coughing. Other possible symptoms include: rapid and shallow breathing, gradual 
and unintended weight loss, fatigue or malaise, aching muscles and joints, and 
clubbing. 6 
 9 
 
Figure 4-Anatomy of Normal Lungs vs. Lungs with IPF: 
A) Normal lungs have an extensive network of expansive, elastic alveoli. 
This network allows for adequate gas exchange and distribution of 
oxygen to peripheral tissues.  
B) Lungs of patients with IPF have less alveoli, which have been replaced 
with constricting and rigid scar tissue. This scar tissue, made up of 
collagen, restricts the expansion of lung tissue and prevents sufficient 
inhalation and gas exchange.  
(Adapted from NHLBI: Idiopathic Pulmonary Fibrosis, 2013 (6)) 
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Diagnosis of IPF is difficult since it presents similarly to other lung 
diseases. A combination of several diagnostic exams is used to confirm the 
pathology, which includes a chest X-ray, a high-resolution computed tomography 
(HRCT) scan, spirometry exam, an arterial blood gas exam, a skin test for 
tuberculosis, exercise testing, and a lung biopsy. An X-ray is done to check for 
scar tissue. A shadow might be seen in the X-ray that indicated the presence of 
scarring, though many patients with IPF have normal X-rays at the time of 
diagnosis.6 An HRCT scan provides a higher quality image than an X-ray and can 
show scar tissue as well as the extent of lung damage. It is more likely to help a 
physician detect IPF at an earlier stage.6 Spirometry is used to measure the amount 
of air that one can breathe out after a deep breath (Figure 5). A patient with IPF 
would not be able to breathe out as much air due to the lung scar tissue (Figure 6).6 
An arterial blood gas test is taken to measure the levels of oxygen and carbon 
dioxide in the blood, which could tell physicians if the patient’s lungs are 
performing gas exchange as they should. This would be deficient in a patient with 
IPF.6 A skin test for tuberculosis (TB) is done to rule out TB as the cause of 
symptoms. If positive, a lump would form where the injection was done on the 
forearm 48 to 72 after the test. An exercise test will show how well gas exchange 
occurs when the body is active. Dyspnea is likely to be exacerbated by activity in a 
patient with IPF.6 Finally, a lung biopsy is the most concrete method to diagnose 
IPF.6 A lung biopsy would consist of taking a sample of lung tissue from the 
patient and putting it under the microscope to check for signs of scar tissue. Once 
 11 
diagnosed, patients with IPF have a median life expectancy of 2.5 to 3.5 years. 
Poorer prognosis is positively correlated with age. 6 
 
 
Figure 5-- Spirometry Results of a Normal Lung: The normal compliance curve 
indicates a normal expansion of lungs. Normal forced expiration curve indicates a 
normal ratio of forced expiratory volume (FEV1) to forced vital capacity (FVC). 
FEV1 is the measure of air one can expire from their lungs in one second. FVC is 
the measure of air one can breathe in and out in one deep breath. A normal 
spirogram indicates a normal range of volumes of air the lungs breathe in and out. 
(Adapted from Johns Hopkins School of Medicine: “Lab: Disease States”, 1994 
(8)) 
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Figure 6—Spirometry Results of a Fibrotic Lung: The fibrosis compliance 
curve shows a decline in expansion of lung tissue. The fibrosis FEV1 to FVC 
ratio is increased, though showing a total decrease in both total volumes. The 
spirogram of a fibrotic lung is significantly condensed, showing a decrease in 
volumes of the lung across the board. 
(Adapted from Johns Hopkins School of Medicine: “Lab: Disease States”, 
1994 (8)) 
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Objectives 
 
The objectives of this thesis are as follows: 
1. To review the literature available to define the relationship between 
telomeres and pulmonary fibrosis in humans. 
2. To discuss and assess the current therapies available for IPF patients with 
telomeropathies.
 14 
PUBLISHED STUDIES 
 
The Role of Telomeres in the Pathogenesis of Idiopathic Pulmonary Fibrosis: 
 Idiopathic pulmonary fibrosis has prompted many research studies in efforts to 
understand its etiology. Among the many avenues researchers have explored for an 
answer to the cause, genetics continue to be amongst them.   
Mutations That Cause Telomere Dysfunction 
TERT and TERC 
Amongst one of the earliest studies done, Armanios, M. et al. (2007) screened 73 
subjects for TERT and TERC mutations. The pedigrees of the six subjects that carried 
heterozygous TERT mutations (8%) were studied to determine if the incidence of the IPF 
phenotype followed the pattern of inherited mutations. The pattern was consistent with an 
autosomal dominant inheritance of the disease in that the mutated allele was present in 
those affected by IPF and generally absent in those who were not carriers. The mutant 
carriers that did not present with IPF were significantly younger, supporting the previous 
indication that the disease was age-dependent. The study further analyzed whether or not 
the mutations correlated with shorter telomere length. It was found that the mutant 
carriers, even those that showed no symptoms, had significantly shorter telomeres on 
average than their non-carrier relatives. When comparing telomere lengths amongst age-
matched subjects, mutation carriers were below the 10th percentile.9  
When studying 134 subjects from 21 unrelated families with heterozygous TERT 
mutations, researchers found that no subjects below the age of 40 presented the 
 15 
pulmonary fibrosis phenotype.10 In contrast, researchers found that 60% of male subjects 
and 50% of the female subjects over the age of 60 presented with clinical IPF.10 Of the 
subjects studied, those with TERT and TERC mutations had shorter telomeres than 
noncarriers (Figure 7). In addition to these findings, it was found that biological family 
members of subjects affected by pulmonary fibrosis but did not have a TERT mutation 
had shorter telomeres than healthy unrelated controls and spouses that married into the 
family.10 This implies that successive generations inherit telomere length regardless of 
inheriting TERT mutations. It could not be concluded as to whether or not those affected 
with short telomeres presented any IPF phenotypes without inheriting the mutations.10 It 
is believed that environmental factors played a role in the prevalence of IPF in the 
subjects with mutations, as 95% of the mutation carriers smoked or had exposure to a 
fibrotic agent. 10 
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Figure 7—Telomere Length in Normal population vs. TERT/TERC Mutation Carriers: 
A) The graph shows the length of telomeres in the normal population. The data represents 
the average telomere length in kilobases (kb) across all age groups. B) The graph shows 
the telomere lengths of noncarriers, mutation carriers, and mutation carriers with the IPF 
phenotype. Both groups of mutation carriers show a lower mean length than noncarriers. 
(Adapted from Diaz de Leon, Alberto et al., 2010 (10)) 
 
In 2008, a study was done to test if telomere shortening was a common incidence 
in the manifestation of IPF in patients without the known TERT or TERC mutations. It 
had been previously established that missense, frameshift, and splice site mutations in 
TERT was found in both familial and sporadic cases of IPF.11 The study reiterated that 
telomere lengths in IPF patients with these mutations were found to be significantly 
shorter and decreasing in circulating leukocytes than those of age-adjusted control 
subjects.11 The study took patients with familial and sporadic cases of IPF and sequenced 
the genes that encode the components of the telomerase, TERT and TERC. The telomere 
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lengths of the circulating leukocytes in both the test and control subjects were analyzed 
using terminal restriction fragment length (TRFL) analysis of genomic DNA. The TRFL 
method consists of digesting DNA into sections and measuring the lengths of the 
fragments. The study inadvertently found six new mutations in TERT.11 In alignment 
with its goals, the results showed that 25% or more of the subjects with familial or 
sporadic IPF has short telomere lengths.11 Of the subjects in the study that had familial 
IPF, a total of 37% showed telomeres below the 10th percentile.11 Of the subject in the 
study that had sporadic IPF, a total of 25% showed short telomeres.11 These statistics 
included both subjects with and without mutations in TERT and/or TERC. The results 
suggested that short telomeres played a role in IPF beyond the mutations. Though, 65% 
of the subjects with coding mutation in either TERT or TERC met the clinical definition 
of IPF. The subjects that carried mutations with a diagnosis of IPF were all above 48 
years old, indicating that pulmonary fibrosis is correlated with aging. Subjects with 
mutations were more likely to pass away over the course of the study than those without, 
as well as subjects with telomere lengths below the tenth percentile versus those with 
lengths above.11 Smoking has been a known risk factor for IPF, but researchers 
speculated that there existed an increased risk for those with mutations, as well.11 The 
male to female ratio of subjects with mutations suggested a greater “penetrance of the 
pulmonary fibrosis phenotype” in males with the dominant telomerase-mutated 
genotype.11 
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RTEL1 
 Mutations in TERT and TERC cannot completely account for the cause of 
telomere dysfunction seen in IPF. Regulator of telomere elongation helicase 1 (RTEL1) 
is a gene that “encodes for a DNA helicase that is responsible for the stability, protection, 
and elongation of telomeres and interacts with proteins in the shelterin complex known to 
protect telomeres during DNA replication.”16 After ruling out TERT and TERC 
mutations as the cause of FPF, a study in France took the DNA of 47 individuals 
diagnosed with familial pulmonary fibrosis (FPF) and performed whole human exome 
sequencing to search for mutations that may play a role in the development of their 
condition. The study discovered a prevalence of RTEL1 mutations in 4 of the subjects 
coming from 4 independent families.16 Whole-blood cell analysis concluded that those 
individuals had shorter telomeres than age-matched controls. Statistics show that up to 
25% of IPF patients and 40% of FPF patients exhibit short telomeres with half of these 
FPF patients carrying TERT or TERC mutations.16 The study proposes that RTEL1 
mutations account for half of the unexplained FPF patients with shortened telomeres.16 
Similarly to patients with TERT mutations, researchers found a history of smoking in a 
majority of the patients with RTEL1 mutations afflicted with IPF.16 
TINF2 
The gene TRF1-Interacting Nuclear Factor 2 (TINF2) codes for one of the 
proteins that make up the shelterin complex that protects telomeres. A family with IPF 
was found to have a heterozygous mutation in TINF2, though there was no evidence of 
shortened telomeres in peripheral blood cells.17 This opens up a new role of telomere 
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dysfunction in IPF that does not result in short telomere lengths.  In mice, it has been 
previously shown that deletion of Trf1 or Trf2 in type II alveolar epithelial cells (AECs) 
results in telomere damage response, senescence, and a pulmonary fibrosis phenotype 
with showing short telomeres.17 
PARN 
Exome sequencing of patients with IPF linked mutations in PARN with shorter 
telomeres.18 When the genetic sequencing of seven relatives with IPF was taken, they 
were all found to have the PARN mutation.18 Though this implicates a role of PARN 
mutations in the pathogenesis of IPF, the pathway through which PARN mutations cause 
telomere dysfunction is still unknown.18  
 
All studies agree that shorter telomeres are associated with worse survival rates in 
patients with IPF. These results are independent of age, sex, and mutations in 
telomerase.19 
 
 
Mechanism of Telomeropathies in IPF 
 
 
  While the exact mechanism behind short telomeres in IPF is unknown, a pathway 
has been proposed. The short telomeres, being dysfunctional, activate a DNA damage 
pathway that ultimately results in cell death or cell cycle arrest. This is seen in the clinical 
setting as tissue death that results in organ failure in tissues that have a high turnover rate 
of cells, such as in the lungs.9 The epithelium of the pulmonary tract is constantly 
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regenerating and replenishing itself, thus IPF manifests with telomere deficiency. This 
mechanism would mean that the fibrosis seen is an indirect result of insufficient alveolar 
epithelium and not a direct consequence of a fibrogenic defect. The proposed 
pathogenesis would lead to lung remodeling. This would explain the lack of success 
associated with anti-inflammatory treatments of IPF.9 This etiology would also help 
explain the effect that smoking has on the risk of developing IPF, as smoking induces 
increased turnover of cells. Paired with the natural shortening of telomeres with increased 
age, smoking could explain the development of pulmonary fibrosis in those with wild-
type telomerase.9  
A mechanism for a specific cell type has been proposed type II alveolar epithelial 
cells as the key player in the pathogenesis. A study found that shortened telomeres in type 
II alveolar epithelial cells causes lung remodeling and fibrosis (Figure 8). Researchers 
found an abundance of senescent cells accumulated in areas of heavy scarring in the 
lungs.20 The lung remodeling occurred with age and did not present with previous lung 
injury or a loss of type II AECs20, reaffirming the preceding theories. In addition, there 
was evidence of DNA-damage response20, providing further support for the suggested 
mechanism. 
In analyzing this mechanism, a more detailed explanation has been suggested.  It 
is known that short telomeres induce the epithelial damage response via apoptotic 
pathways.22 When the epithelial tissue of the lung is damaged, it requires regeneration of 
the dead tissue, as mentioned earlier. When the body interprets the cell death issue as 
tissue damage, it will initiate proliferation of cells that produce and deposit collagen 
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fibers.22 The epithelium will release an increased amount of fibrogenic mediators—
growth factors—in response. These mediators activate mesenchymal cells. Mesenchymal 
cells take the form of fibroblasts and myofibroblasts, which cause the build-up of scar 
tissue that is seen in IPF.22  
 
Figure 8: Proposed Pathway From Telomeropathy to IPF: On the right, the steps of the telomere-
related mechanism of IPF pathology are shown. Short telomeres and AEC injury (and regeneration) leads 
to DNA damage which causes the activation of apoptosis pathways. This leads to the recruitment of 
fibroblasts, which produce and deposit collagen. On the left, the figure shows the desired modifications that 
would reverse the issues that arise at each step of the pathway. (Adapted from Povedano, Juan Manuel, et 
al., 2018 (21)) 
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The Role of Growth Factors in IPF 
The proliferation of these mesenchymal cells is a downstream consequence of 
tyrosine kinase receptors being activated on the extracellular surface. The molecules that 
activate these receptors are known as growth factors. The families of growth factors that 
play a role in IPF are platelet-derived growth factor (PDGF), vascular endothelial growth 
factor (VEGF), and fibroblast growth factor (FGF). PDGF is released in response to 
damaged tissue and acts to promote wound repair and the development of scar tissue.22 In 
IPF, PDGF has been to shown to stimulate the proliferation of fibroblasts, which deposit 
the collagen in the lungs22. VEGF is important for survival and differentiation of 
endothelial cells in the lung and is, in part, responsible for the maintenance and repair of 
the lung.22 In IPF, VEGF has been shown to increase permeability of blood vessels in the 
lungs for factors that increase remodeling and wound healing. Thus, if VEGF is activated 
in response to a perceived tissue injury in the lungs, it would increase the deposition of 
collagen and formation of scar tissue in the lungs. FGF is a family of growth factors that 
play a role in the regulation of most processes related to tissue injury response. FGF acts 
to aid regulation of “[cell proliferation, differentiation, angiogenesis, wound healing, 
fibroblast proliferation, and production of collagen].”22 In IPF, the family of FGFs has 
been shown to induce proliferation of fibroblast in the lung, which causes synthesis of 
connective tissue.22 The role of these growth factors provide a target for IPF therapy. 
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Telomeropathies Manifestations 
In addition to causing IPF, short telomeres have manifested a number of other 
conditions. At Brigham and Women’s Hospital (BWH) in Boston, Massachusetts, a small 
pilot study looking to establish screening practices for subjects with clinically diagnosed 
IPF who had the potential to have underlying short telomeres or telomerase mutations 
was established in 2011.23 This study emerged following a case in which a patient with 
IPF underwent lung transplant, but subsequently developed severe bone marrow and liver 
failure. The association with these three organ systems was suggested to be related to 
telomeropathy given the known organ dysfunction associated with functional mutations 
in genes responsible for telomere homeostasis.23 
         In September 2011, the lung transplant program at BWH published a protocol and 
clinical guidelines to choose potential study subjects. Inclusion criteria were patients that 
had two or more visits to physicians within the lung transplant program and exclusion 
criteria were those patients that had connective tissue disease (CTD) or sarcoidosis-
associated IPF. The protocol involved screening patients for the following: 
·      Abnormally low complete blood count (CBC) values including white blood cells, 
platelets, and hematocrit 
·      High mean corpuscular volume (MCV)—or large average size of red blood cells 
·      Family history of IPF, aplastic anemia, or liver disease 
·      Abnormal liver enzymes and function 
·      Abnormal liver findings on imaging such as ultrasound or CT scans 
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Those subjects that met one of the above criteria as well as the inclusion criteria had their 
telomere length checked by flow fluorescence in situ hybridization. Those with telomere 
lengths shorter than the 10th percentile of the population were qualified as having short 
telomeres. These patients were sent for further bone marrow and liver testing as part of 
their lung transplant work up.23 Additionally, those who were characterized as having 
short telomeres were consented for further genetic testing in regards to functional 
mutations in the TERC and TERT genes.23  
         During the enrollment period from September 2011 to December 2013, 127 
subjects were eligible for inclusion based on the criteria of having IPF not associated with 
sarcoidosis or CTD and having two or more visits to the lung transplant program 
outpatient clinic in that time. Of the 127 subjects, 30 of them were suspected of having 
short telomeres because they met at least one of the screening criteria as defined above. 
Of the 30, 22 were consented for telomere length testing. The other eight did not on the 
basis of either being too well to be considered for lung transplantation in the near future, 
being rejected for transplant for other reasons, or having passed away in the enrollment 
period.23 Fifteen of the 22 people that had their telomere length checked were found to 
have short telomeres.23 Of the subjects with short telomeres, seven agreed to genetic 
testing. Of those seven subjects, two patients were found to have mutations in TERT 
believed likely to be pathogenic because they caused coding abnormalities, three patients 
were found to have a variant of TERT that was previously found to be a benign mutation 
given no changes in coding sequence of the protein, and two patients had no mutations in 
either gene.23  
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Interestingly, it was found that macrocytosis (high MCV of red blood cells) had a 
positive predictive value of 86.6% in recognizing patients with short telomeres as 13 of 
15 patients with short telomeres had an MCV above the limit of normal.23 In the patients 
with short telomeres, 13 of them underwent bone marrow biopsies to better characterize 
marrow disease, even when their peripheral blood showed few abnormalities (such as 
mild anemia and macrocytosis). Significant abnormalities were found in the marrows of 
eight of the 13 patients that underwent these biopsies.23  
In addition to the exploration of bone marrow abnormalities, investigators 
inquired as to subclinical liver dysfunction. Of the 15 patients with short telomeres, one 
had abnormal liver function tests on blood work and seven of them underwent liver 
biopsies.23 On biopsy, six of seven samples had abnormalities ranging from mild 
regenerative changes to mild portal chronic inflammation.23 Notably, none of the patients 
had cirrhosis. The results of this study were consistent with the hypothesis that short 
telomeres can cause a spectrum of diseases that lead to multiorgan failure include lung, 
bone marrow, and liver.23 
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Most Notable Treatment Options to Date 
 
 
N-Acetylcysteine, Azathioprine, and Prednisone & Pirfenidone 
 
In 2011, clinical trials of treatments for IPF included N-acetlcysteine used in 
combination with prednisone and azathioprine. N-acetylcysteine is an antioxidant and 
combined with prednisone, a corticosteroid, and azathioprine, an immunosuppressive 
drug, did produce a slowing of the “rate of decline in forced vital capacity and diffusing 
capacity for carbon monoxide” after a year of treatment.7 These observations, however, 
were not of definitive clinical significance. Clinical trials of treatment also included 
pirfenidone. Pirfenidone, a compound that works by down-regulating growth factors such 
as transforming growth factor-beta (TGFβ) also decreased the rate of decline in vital 
capacity, as well as increase the survival time over the course of a year.7 A clinical trial in 
which prednisone and an anticoagulant were administered was suspended by the National 
Heart, Lung, and Blood Institute (NHLBI), as they felt there would be no added effect in 
treatment of IPF.6,7 Pirfenidone is the only choice of these treatments for IPF with 
positive clinically significant results, but is not a cure and cannot resolve telomere 
dysfunction. 
 
 
Danazol 
A study done in 1999 showed that estrogen, a steroid hormone, activates 
telomerase by acting on the TERT promoter.24 Estrogen activates transcription of the 
TERT gene, which promotes activation of the telomerase enzyme to elongate telomeres.24 
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This study laid the foundation for the experimental hormonal activation of telomerase. 
While the initial intent of the study was to observe the effect of estrogen on telomerase in 
the endometrium, it later inspired further research into how steroid hormones could be 
used as treatments for telomeropathies.24 
Androgens have been used to treat bone marrow deficiency.25 Androgens were 
found to normalize telomerase activity in the subjects with loss-of-function mutated 
TERT alleles.25 The study claimed that these findings could suggest possible treatment 
options for “patients with aplastic anemia carrying telomerase complex mutations and in 
dyskeratosis congenita, ”-- two illnesses with a telomerase-deficient etiology.25 The 
results of the study established the mechanism for activation. TERT is expressed when 
aromatized sex hormones (estrogen metabolites) bind to the estrogen receptors, which 
then locates and binds to the DNA binding sequence (ERE) located in the TERT 
promoter region (Figure 9).25 Knowing that estrogen metabolites are formed from 
aromatized androgens, this mechanism suggests that androgens are converted before 
binding to ERs in leukocytes.25 
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Figure 9—Sex Hormones Induce Telomerase: As the concentration of the 3 synthetic 
sex hormones increase, upregulation of telomerase activity increases.  
(Adapted from Calado, Rodrigo T., et al., 2009 (25)) 
 
As mentioned previously, short telomere syndromes result in other clinical 
manifestations in addition to lung fibrosis. Bone marrow deficiency and liver cirrhosis 
have been well characterized in patients with short telomeres as a result of loss-of-
function mutations in telomerase genes (TERT and TERC in particular).26 Male steroid 
hormones have been used for decades to increase the production of red blood cells by 
defective bone marrow and it is that observation that lead Townsley et al. (2016) to study 
the effects of danazol on the length of telomeres in patients with short telomere 
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syndrome. In this two-year prospective study, patients with telomere lengths in the 10th 
percentile or less were given oral doses of danazol daily and their telomere lengths (as 
well as blood counts, liver function tests, and pulmonary function tests) were evaluated 
every six months. A majority of patients experienced a significant lengthening of 
telomeres shortly after beginning danazol treatment (Figure 10).26 Additionally, those 
patients receiving danazol had increased red blood cell count and no progression of their 
lung disease as compared to their counterparts in the study that were not receiving 
danazol, suggesting that the elongation of telomeres has a therapeutic effect on the 
clinical progression of the disease. 26 
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Figure 10—Telomere Length Increases After Danazol 
Administration:  A) The length of telomeres (in kilobase pairs) 
of the 12 patients enrolled in the study receiving daily doses of 
800mg of danazol at the end of 2 years. The dotted line represents 
the previously decided upon threshold for significant increase in 
length as compared to baseline. All 12 patients met that criterion. 
B) The change in length of telomeres in patients taking danazol as 
compared to their baseline at 6, 12, 24, 30, and 36 months. Fine 
dotted line represents the average decay of telomeres in healthy 
individuals (~60 bp/year) and bold dotted line represents the rate 
of decay in patients with short telomere syndrome (~120 bp/year). 
These results show danazol increased length of telomeres in 
patients with short telomere syndrome, but the effects were lost 
after the discontinuation of danazol at 24 months.  
(Adapted from Townsley, Danielle M., et al., 2016 (26)) 
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The Use of Nintednaib 
Nintedanib, a receptor tyrosine kinase (RTK) inhibitor, was studied in vitro as a 
potential treatment for IPF. Lung fibroblasts were extracted from patients with IPF and 
control, non-fibrotic subjects and nintedanib was applied. The goal was to observe 
whether or not there was a decrease in the deposition of extracellular matrix (ECM) and a 
proliferation of the cells that produce this ECM. It was found that nintedanib prevented 
fibroblast proliferation caused by growth factors (Figure 11) and collagen production was 
significantly reduced.27 The drug acted to block the receptors of the growth factors 
PDGF, FGF, and VEGF (Figure 12), which have been found to play a role in IPF. 27 
 
 
Figure 11—Nintedanib Concentration vs. Percent Growth Factor 
Inhibition: Ninteanib concentration positively correlates with inhibition of 
FGF and PDGF in cells of mice with IPF and mice without IPF. This shows 
that nintedanib is a generalized inhibitor regardless of growth factor 
concentration. 
(Adapted from Hostettler, Katrin E., et al., 2014 (27))  
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Figure 12—Nintedanib Mode of Action: The figure shows the molecules of nintedanib 
directly attacking the areas of fibrosis, preventing proliferation of myofibroblasts (green 
cells) and migration of growth mediators. The abnormal count of myofibroblasts and 
irregular migration of interstitial fibroblasts are an indication of the IPF phenotype. The 
transition of type II AEC to myofibroblast (or epithelial-mesenchymal transition, denoted 
as EMT) seen in the top left corner of the figure is also a sign of IPF. (Adapted from 
Wollin, Lutz, et al., 2015 (28))  
 
The effectiveness of adding statins to the nintedanib treatment course was 
observed in a clinical trial completed in 2017.29 Subjects were split into a total of four 
groups: 192 patients receiving both statins an nintedanib group, 120 receiving only statins 
and a placebo, 446 patients receiving only nintedanib, and 303 in a placebo group. When 
 33 
comparing the two placebo groups, researchers found there was no statistically significant 
difference in progression of IPF.29 This implies that there was no harm done in 
administering the statins, though there also was no benefit. The study also determined 
that there was no statistically significant difference between the subjects taking 
nintedanib and statins and the subjects only taking nintedanib.29 Though the study notes a 
numerical difference in both comparisons, without a statistical significance, no 
correlation can be made. The addition of statins to the nintedanib did produce some 
increase in adverse affects, such as an increase in diarrhea occurrence and an increase in 
major adverse cardiac events.29 The researchers do not mention the statistics of these 
findings, however, it is claimed to have been “expected.”29 
 
Low Dose Inhaled Carbon Monoxide 
 Carbon monoxide (CO) is endogenously produced in the body with a variety of 
functions in normal biological processes such as “protection against oxidative injury and 
cell injury, inhibition of cell proliferation, suppression of matrix production and 
inflammation, and increased fibrinolysis.”31 These are all important factors in IPF and 
therefore, presented CO as a potential treatment option. A clinical trial of low-dose 
inhaled CO was executed in a randomized, placebo-controlled study with 29 subjects in 
each group. The placebo group received oxygen (21%) and the experimental group 
received 100 or 200 ppm CO gas via facemask. The result of the trial showed no 
statistically significant difference in either group, meaning the CO was not shown to be 
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effective as a treatment option.31 Though the researchers reported a number non-serious 
and serious adverse effects, it has been shown that inhaled CO is safe to administer.31 
 
 
Stem-Cell Therapy  
Amongst the stem cell research done, the study completed with somatic cell 
nuclear transplant (SCNT) of telomere haplo-insufficient cells from mice was successful 
in producing naïve pluripotent stem cells, as well as elongated telomeres.  Somatic cell 
nuclear transplant takes the DNA from one somatic cell and places it is another. In this 
particular study, the somatic cells used are adipose stem cells (ADSCs). This provided an 
opportunity for a potential patient-specific treatment for IPF patients. The researchers 
took cells from mice with heterozygous TERC mutations and replaced the mutated DNA 
with wild-type TERC cells’ DNA. In using adipose cells, this particular treatment was 
intended to address a theory that the pathology of IPF originates in an activated immune 
pathway—a theory that rivals the injury-based etiology described earlier. Researchers 
used these mesenchymal stem cells (MSCs) because, as immune-privileged cells (cells 
that do not produce immune responses), they possess anti-inflammatory effects—effects 
that dampen the response to infection. In agreement with the studies that indicate the 
mechanism is injury-based,9,20,22 the trial executed with IPF patients showed no clinically 
significant benefit of the treatment. 32,33 
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GRN510 
 In 2013, a study of the small molecule activator, GRN510, had a promising 
conclusion. The study found that the small molecule activated telomerase in lung and 
bone marrow tissue in mice with induced pulmonary fibrosis (Figure 13).34 This resulted 
in a conclusion that GRN510 increased the telomere length and ameliorated changes lung 
structure and function.34 While the mechanism of action of the molecule could not be 
concluded, it worked on lung epithelial cells, not lung fibroblasts.34 The combination of 
positive results seen with GRN510 use and the conclusion that the molecule acts on lung 
epithelial cells34 correlates with the proposed mechanism of type II AECs in IPF 
pathology.20 The authors of the study suggested that the activator up-regulated TERT.34 
Though this analysis had positive results, the experiment was done with mice and, 
therefore, requires further studies to establish if it is effective as a treatment in IPF 
patients. 34 
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Figure 13—GRN510’s Effect On Telomerase Activity in Lung Epithelial Cells and 
Fibroblasts: The graph shows the upregulation of telomerase activity (TA) in small 
airway (bronchial) epithelial (red) with increasing concentration of GRN510. The graph 
also shows a minimal increase in TA in lung fibroblasts (green) at maximum 
concentration of GRN510, 1uM. This correlates with the mechanism of the role of 
epithelial cells in IPF. (Adapted from Le Saux, Claude Jourdan, et al., 2013 (34)) 
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DISCUSSION 
 
 The literature available on the role of telomeropathies in idiopathic pulmonary 
fibrosis all seems to agree that, regardless of the cause of the etiology, telomere 
dysfunction commonly causes lung fibrosis. Short telomeres have been found in 
pulmonary leukocytes, type II AECs, and myofibroblasts in patients with IPF. The 
current mechanism supported is one in which telomere dysfunction leads to the activation 
of an epithelial cell injury pathway. This pathophysiology of IPF is supported both by 
literature specifically published on the matter and in studies that analyze the effectiveness 
of treatments. The treatment options that target this mechanism have been shown to be 
more effective. The studies available show that telomere dysfunction can result from a 
variety of known telomerase and shelterin complex mutations, but that there is also still 
unknown causes. TERT and TERC mutations account for half of telomere-related FPF 
cases and RTEL1 mutations may account for up to half of the rest of the telomere-related 
FPF cases.  
 The studies presented did, however, have limitations. The study performed by 
Diaz de Leon, Alberto et al (2010) was limited due to the familial nature of the patients. 
The rate of incidence was likely to be higher than with subjects of a random population 
study.10 In addition, due to the observational nature of the study, not all the subjects 
received the same work up to establish an IPF diagnosis.10 The rate of incidence within 
any family could have been lower or higher than reported depending on the variable 
diagnostic guidelines. There was also a prevalence of bias as a result of collecting 
information on patients with lung disease. The subjects diagnosed with IPF were more 
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likely to report environmental conditions that support their diagnosis.10 Despite these 
limitations, the study confirmed the relationship between age and the manifestation of 
IPF.  
 The study done by Armanios, M Y, et al. (2007) was limited by the size of the 
sample of the subjects and conclusions made should be verified by a larger scale study. 
Understanding this limitation, telomere lengths were found to be below the 10th percentile 
and this is difference is significant enough to reasonably accept the relationship between 
mutation and telomere length proposed. The research done with respect to the prevalence 
of short telomeres regardless of mutations by Cronkhite, Jennifer T. et al. (2008) was 
completed before whole-exome sequencing discovered the telomere –related mutations 
unrelated to TERT or TERC.11 It was unknown if there were other mutations present 
causing the manifestation of IPF. It was also unknown that the degree of telomere 
shortening in circulating leukocytes was representative of cells in the lung environment.11 
Researchers cannot be certain that the telomere lengths of the peripheral cells measured 
in the study would be the same as cells in the lungs of the subjects.  The finding that more 
patients with mutations or with telomeres below the tenth percentile died over the course 
of the study than subjects without mutations or with telomere lengths above the tenth 
percentile was not found to be statistically relevant.11 The TRFL assay is not a direct 
measurement of telomere lengths, as its undigested lengths of DNA contain both 
telomeres and subtelomeric segments. While the researchers attempted to minimize the 
subtelomeric segments with multiple restriction enzymes, this could be a source of error 
in measure of telomere length.11 Despite this possible source of error, results of telomere 
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lengths recorded at below the 10th percentile (significantly shorter than the average) are 
likely able to withstand scrutiny. 
 The study that compiled the extrapulmonary effects of short telomeres23 had many 
limitations, most notably low power and the issue of validity due to the narrow scope of 
the subjects (i.e. all chosen from one center). Additionally, the inclusion criteria featured 
patients who were being evaluated for lung transplant, signifying substantially advanced 
disease, which is likely to be correlated with multiorgan dysfunction, regardless of the 
relationship the researchers found with telomere length. However, the results of this small 
pilot study were promising and offered a new screening tool for patients with IPF and 
allowed for further genetic testing in family members at risk of developing disease.  
 While IPF is a relatively rare disease, with telomere-deficient IPF affecting an 
even smaller subgroup, the rate of incidence increases annually. There have been, and 
continue to be, a variety of studies done in efforts to provide a substantial treatment plan. 
Some of the treatment plans discussed specifically target the telomere dysfunction in 
telomere-related IPF, while others address the direct causes of symptoms of IPF. The 
longest-running treatment option to date is lung transplantation.7 It is equivalent to a 
“band-aid solution” and only approximately 44% of patients have shown a survival time 
of 5 years post-transplant.7 This means a transplant cannot be considered a cure for the 
condition. N-Acetylcysteine, administered either alone or in combination with prednisone 
and azathioprine, was at one point the standard choice of treatment, but has not been 
clinically significant as an effective treatment.6 Though the treatment showed a decrease 
in the decline of FVC, the results were not considered statistically significant.6 This 
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treatment plan should not be recommended to patients by their physicians. Pirfenidone, 
though shown to be clinically significant, is not a cure for IPF and does not resolve the 
issue of telomere dysfunction.  
 While low-dose carbon monoxide was found to be effective in experimentally 
induced pulmonary fibrosis in a study done with mice, it was found to have no effect as a 
treatment in a clinical trial. The researchers reported no specific limitations of their study, 
though they reported that the CO was safe when they also reported a number of both 
serious and non-serious adverse effects. Low-dose CO should not be considered as a 
viable treatment option. 
 The clinical trial that tested the effectiveness of danazol showed great promise.  
Of the 12 patients that stayed with the trial for the entire 24 months, 11 showed an 
average of 30% telomere attrition. In addition to this observed attrition, the telomeres of 
these patients elongated by 386 base pairs, on average. This elongation seemed to occur 
in the patients with TERT mutations more so than the other patients, though it could not 
be concluded that danazol works by up-regulating TERT. The study also claims 
hematologic improvements accompanied treatment. The study evaluated its own 
limitations, among which were being unable to identify mutations in all patients, not 
measuring telomere attrition for a longer period, using the highest dosage of danazol 
approved for humans, and not having a randomized study with a control group. In being 
unable to identify mutations in all patients, the genetic heterogeneity could have resulted 
in a biased measurement of the estimated telomere attrition rate. This applies for the 
shorter observation time, as well. In using the highest dosage of danazol, side effects 
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were possibly worsened and the study suggests that a follow up study be done to 
determine appropriate dosing. A lack of randomization and a control group in a clinical 
trial increases bias. In addition to this, it should be observed that the study was done with 
a very small group of subjects, and increasingly became smaller as patients dropped out 
through the 36 months of the trial. This makes it difficult to conclude the efficacy of the 
trial. With an ongoing clinical trial attempting to establish appropriate dosing,35 danazol 
is a worthy option for treating telomere-related IPF. 
 The 2013 study done with the small molecule activator, GRN510, had a 
promising conclusion. Though this analysis had positive results, the experiment was done 
with mice and, therefore, requires further studies to establish if it is effective as a 
treatment in IPF patients. In addition, the study was performed on mice with induced 
TERT mutations, which brings into questions the validity of using GRN510 to treat IPF 
related to other mutations. While GRN510 was shown to increase telomerase activity, 
this may not be the result in cells with telomere dysfunction due to other mutations. 
Without a clinical trial to draw conclusions from, GRN510 is still far from being a 
reasonable therapy choice for IPF. 
 The experiment done with SCNT of telomere haplo-insufficient cells from mice 
was successful in producing naïve pluripotent stem cells, as well as elongated telomeres. 
This was not the case in a longitudinal clinical study. The study claims no relationship 
can be defined between the stem cell therapy and disease progression, as its effectiveness 
was not being observed. However, the results of the study indicate no change in the 
disease progression than that in patients receiving only pirfenidone. Stem cell therapy, 
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though a patient-specific therapy, cannot currently be considered an option for IPF 
treatment. 
 The small-molecule tyrosine kinase inhibitor, nintedanib, showed itself to 
have a potent inhibitory effect on the proliferation and migration of human lung 
fibroblast in the clinical trials completed in 2015. The two-phase study was double-blind 
and placebo-controlled and in both phases, nintedanib showed a slowed annual rate of 
decline in FVC versus the placebo group. The study showed many adverse effects, which 
brings into questions the safety of long-term use. In addition, a case study described 
below indicates that physicians should monitor discontinuation of its use.  
In two cases of IPF, 3 weeks after cessation of nintedanib, the patients’ conditions 
deteriorated rapidly. One patient was brought into the hospital 3 weeks after 
discontinuing nintedanib with a worsened dyspnea on exertion, tachypnea, respiratory 
failure, and bilateral crackles could be heard. No other change of medicine or 
environment occurred and no signs of infection could be detected. Three months later the 
patient died as a result of a spontaneous pneumothorax.29 The second case consisted of a 
patient who had been administered nintedanib 3 weeks prior to admission and had to 
discontinue that line of treatment while under hospital care due to a nonstop loss of 
appetite. The patient’s condition deteriorated soon after, requiring oxygen to be 
administered even at rest. There was no sign of infection and antibiotics showed no 
improvement.29 In both cases, other possibilities for exacerbation had been ruled out. 
Infection drug toxicity, inhaled antigens, and congestive heart failure were denoted 
unlikely as causes.29 The physicians who admitted these patients strongly believed that 
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the rapid deterioration of their condition was due to the cessation of nintedanib and urge 
physicians to monitor any plans to discontinue the medication as a course of treatment 
closely. It has previously been discovered that the discontinuation of tyrosine kinase 
inhibitors in other conditions have correlated with a disease flare, though the underlying 
mechanism is not understood.29 
Though its discontinuation should be monitored more closely and a clinical trial 
should be administered to establish appropriate dosing, nintedanib is a strong option for 
effectively decreasing the fibrosis caused by any etiology of IPF.   
 In a follow-up study, statins were tested as treatment, both alone and in 
combination with nintedanib.30 The study was not randomized and, therefore, no 
causality can be established. The study concludes that future prospective studies of the 
effects of statins in the treatment of IPF are needed.30 There is no evidence in the results 
of the present study that indicate that this would be beneficial. The results show no 
statistically significant benefit of the use of statins and report an increase in adverse 
events.  
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CONCLUSION 
 
 In conclusion, it is shown that telomere dysfunction is highly correlated with IPF 
diagnoses. The mechanism with the most supporting evidence is that shortened telomeres 
activate an epithelial injury pathway that results in proliferation of cells that produce and 
deposit collagen in the lungs. Danazol is the most supported telomere-directed treatment, 
though a clinical trial of lower dosing should be completed. This drug could also be a 
potential preventative measure in those with telomere-related FPF in their pedigree. 
Nintedanib is the supported choice for all cases of IPF, as it targets fibrosis in a direct 
fashion. After appropriate dosing of each drug has been established (and proven to be 
nontoxic), a combination of the two drugs should be tested for patients with telomere-
mediated IPF. Targeting telomere attrition and lengthening could prevent further 
manifestations of telomeropathy, while an RTK inhibitor could reverse the prevalent 
condition.   
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